Larvol Delta - ARC401--a-triple-payload-firstinclass-ADC-against-Nectin4-designed-to-overcome-cancer-resistance-and-tumor-heterogeneity-shows-broad-antitumor-activity-and-high-tolerability-in-rats-and-nonhuman-primates

Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer

Trodelvy (sacituzumab govitecan-hziy) - Gilead

ARC-401 - Otsuka

https://www.abstractsonline.com/pp8/#!/21436/presentation/11404

Isabella Attinger-Toller1; Philipp Probst2; Romain Bertrand1; Rachael Fay1; Lia Kallenberger1; Ramona Stark1; Patrick Maurhofer1; Emma Renard1; Roger Santimaria1; Bernd Schlereth1; Dragan Grabulovski1; Philipp Rene Spycher1

Mar 18, 2026